/ /

  • linkedin
  • Increase Font
  • Sharebar

    Novel therapies abound in pipeline

    What clinicians should know about drugs, biologics in development for various diseases

     


    References

    1. Novack GD. Pipeline: Investing in new therapies for ocular surface disease. Ocul Surf. 2015;13:263-267.
    2. Novack GD. Chemistry matters! Ocul Surf. 2017;15:264.
    3. Novack GD. Unapproved Ophthalmic Drugs. Ocul Surf. 2016;14:317-320.
    4. Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74:2211-2215.
    5. Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26:287-296.
    6. Novack GD. What Determines How Much Your Patient Pays for Their Medication in the United States? Am J Ophthalmol. 2016;167:48-51.

     

     

    Gary D. Novack, PhD, is the founder and president of PharmaLogic Development Inc., a provider of strategic and operational services to the pharmaceutical and biomedical industries through the pharmaceutical, biologic, and device development processes. Founded in the late 1980s, PharmaLogic has contributed to 50 FDA product approvals and clearances.

    Over this period, Dr. Novack provided key support in the development and approval of the first pharmacological treatment for macular degeneration, the first site-active corticosteroid, the first and second intravitreal drug delivery systems, and the first neurological indications for botulinum toxin. Through thousands of projects, the company has served more than 500 clients on four continents on and contributed to more than 100 Investigational New Drug (IND) and Device Exemption (IDE) submissions. According to Dr. Novack, PharmaLogic’s consistent success and extensive experience have been the key to becoming a premier services provider to top specialty pharmaceutical and medical device clients.

    Dr. Novack is the author of more than 260 peer-reviewed publications, and an active member and frequent presenter in professional ophthalmic organizations. Most recently, he chaired a subcommittee for the Tear Film and Ocular Surface Society Dry Eye Workshop II. He is on the editorial board of The Ocular Surface, the Journal of Ocular Pharmacology and Therapeutics, and Eye & Contact Lens.
    He has had a lifelong relationship with the University of California, first, as a student and trainee at UC Santa Cruz, UC Davis and UCLA. He then served in many leadership roles including UC Regent, president of the UC Santa Cruz Alumni Association, and president of the UC Santa Cruz Foundation. He is currently visiting professor of pharmacology and ophthalmology at the University of California, Davis, School of Medicine. He is a consultant for numerous pharmaceutical and medical device firms. 

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results